Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Cash from Financing Activities (2016 - 2025)

IGC Pharma (IGC) has disclosed Cash from Financing Activities for 16 consecutive years, with $3.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities rose 291.69% to $3.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.1 million, a 28.84% increase, with the full-year FY2025 number at $4.5 million, up 26.31% from a year prior.
  • Cash from Financing Activities was $3.1 million for Q3 2025 at IGC Pharma, up from $851000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $14.2 million in Q1 2021 to a low of -$1000.0 in Q4 2021.
  • A 5-year average of $1.7 million and a median of $696500.0 in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: tumbled 100.14% in 2022, then skyrocketed 250800.0% in 2024.
  • IGC Pharma's Cash from Financing Activities stood at -$1000.0 in 2021, then surged by 10300.0% to $102000.0 in 2022, then crashed by 100.98% to -$1000.0 in 2023, then soared by 34600.0% to $345000.0 in 2024, then skyrocketed by 801.45% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Cash from Financing Activities are $3.1 million (Q3 2025), $851000.0 (Q2 2025), and $805000.0 (Q1 2025).